Significance of Aspergillus spp. isolation in defining cases of COVID-19 Associated Pulmonary Aspergillosis - CAPA

Imagem de Miniatura
Arquivos
art_COCIO_Significance_of_Aspergillus_spp_isolation_in_defining_cases_2023.PDF (721.49 KB)
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2023
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER BRAZIL
Autores
RICILUCA, Katie Cristina Takeuti
ANDRADE, Tania Sueli de
MARTINEZ, Roberto
BOLLELA, Valdes Roberto
Citação
BRAZILIAN JOURNAL OF INFECTIOUS DISEASES, v.27, n.4, article ID 102793, 10p, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
COVID-19-Associated Pulmonary Aspergillosis (CAPA) is a relatively common complica-tion in patients with severe forms of the disease caused by the SARS-CoV-2 virus. Diag-nosing and confirming CAPA is challenging. In this study, Aspergillus spp. isolation in respiratory specimens from patients with COVID-19 was evaluated for identifying cases of CAPA. In 2020-2021, 17 Aspergillus spp. were isolated from 15 COVID-19 patients admit-ted to a university hospital in Brazil. Patient records were retrospectively reviewed to obtain clinical-epidemiological data and other markers of Aspergillus spp. infection and then compared with the ECMM/ISHAM criteria for defining CAPA. Probable CAPA was defined in 5/10 patients, who had Aspergillus spp. isolated from Bronchoalveolar Lavage (BAL) or a positive galactomannan blood test. Additionally, anti-Aspergillus antibodies were detected in two of these patients, during active or follow-up phases of CAPA. In another seven patients with Aspergillus spp. isolated from tracheobronchial aspirate or sputum, CAPA was presumed, mainly due to deterioration of clinical conditions and new lung imaging suggestive of fungal infection. Antifungal agents to control CAPA, particu-larly voriconazole, were used in 9/15 cases. In cases of probable CAPA and remaining patients, clinical conditions and comorbidities were similar, with lethality being high, at 60% and 71%, respectively. The number of CAPA cases defined by scientific criteria was lower than that assumed in the clinical context. This was largely due to the lack of BAL collection for fungal culture and the non-intensive use of other markers of invasive asper-gillosis. The isolation of Aspergillus spp. in different respiratory specimens should alert clinicians to the diagnosis of CAPA.
Palavras-chave
CAPA, COVID-19, Matrix-assisted laser desorption, ionization, Aspergillus spp, SARS-CoV-2, Invasive aspergillosis
URI
https://observatorio.fm.usp.br/handle/OPI/56051
Referências
  1. Castro-Fuentes CA, 2022, PATHOGENS, V11, DOI 10.3390/pathogens11111227
  2. Armstrong-James D, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.02554-2020
  3. Bellanger AP, 2022, MED MYCOL, V60, DOI 10.1093/mmy/myac031
  4. Blot SI, 2012, AM J RESP CRIT CARE, V186, P56, DOI 10.1164/rccm.201111-1978OC
  5. Bounhiol A, 2022, J MYCOL MED, V32, DOI 10.1016/j.mycmed.2022.101290
  6. Brandi N, 2022, DIAGNOSTICS, V12, DOI 10.3390/diagnostics12071617
  7. Carbonell N, 2022, BIOMEDICINES, V10, DOI 10.3390/biomedicines10071683
  8. Casalini G, 2022, J FUNGI, V8, DOI 10.3390/jof8090894
  9. Cocio TA, 2021, BRAZ J INFECT DIS, V25, DOI 10.1016/j.bjid.2021.101607
  10. Donnelly JP, 2020, CLIN INFECT DIS, V71, P1367, DOI 10.1093/cid/ciz1008
  11. Egger M, 2022, J FUNGI, V8, DOI 10.3390/jof8040390
  12. Fischer T, 2022, DIAGNOSTICS, V12, DOI 10.3390/diagnostics12051201
  13. Hong W, 2022, CLIN IMAG, V90, P11, DOI 10.1016/j.clinimag.2022.07.003
  14. Huang SF, 2023, J MICROBIOL IMMUNOL, V56, P442, DOI 10.1016/j.jmii.2022.12.004
  15. Janssen NAF, 2021, EMERG INFECT DIS, V27, P2892, DOI 10.3201/eid2711.211174
  16. Kim SH, 2022, J KOREAN MED SCI, V37, DOI 10.3346/jkms.2022.37.e134
  17. Koehler P, 2020, LANCET INFECT DIS, V21, pE149, DOI 10.1016/S1473-3099(20)30847-1
  18. Kumar Arjun, 2022, Recent Adv Antiinfect Drug Discov, V17, P167, DOI 10.2174/2772434417666220720122042
  19. Kundu R, 2022, CURR FUNGAL INFECT R, V16, P47, DOI 10.1007/s12281-022-00432-2
  20. Lee R, 2022, KOREAN J INTERN MED, V37, P851, DOI 10.3904/kjim.2022.069
  21. Li Y, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01209
  22. Lupia T, 2022, J FUNGI, V8, DOI 10.3390/jof8121264
  23. Nair AV, 2022, RADIOLOGIA-MADRID, V64, P533, DOI 10.1016/j.rx.2022.06.006
  24. O'Shea M, 2022, J HOSP INFECT, V129, P203, DOI 10.1016/j.jhin.2022.07.023
  25. Ogawa Y, 2023, J INFECT CHEMOTHER, V29, P239, DOI 10.1016/j.jiac.2022.11.001
  26. Pavone P, 2023, MYCOSES, V66, P219, DOI 10.1111/myc.13545
  27. Pemán J, 2020, REV IBEROAM MICOL, V37, P41, DOI [10.1016/j.raim.2020.07.001, 10.1016/j.riam.2020.07.001]
  28. Rouzé A, 2022, CURR OPIN CRIT CARE, V28, P470, DOI 10.1097/MCC.0000000000000977
  29. Ruiz-Ruigómez M, 2022, J FUNGI, V8, DOI 10.3390/jof8080840
  30. Song WM, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.657006
  31. Swain S, 2022, MYCOSES, V65, P57, DOI 10.1111/myc.13369
  32. Verweij PE, 2020, INTENS CARE MED, V46, P1524, DOI 10.1007/s00134-020-06091-6

Coleções
Artigos e Materiais de Revistas Científicas - FM/MDT
Artigos e Materiais de Revistas Científicas - COVID-19
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/53
Artigos e Materiais de Revistas Científicas - LIM/56
Artigos e Materiais de Revistas Científicas - ODS/03